Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,160 from $1,085 and keeps a Buy rating on the shares. The firm is removing sales for TED from its model following the recent Vyvgart setback in TED, while increasing its peak sales estimates in gMG to $6.7B from a previous $5.7B and to $4.96B from a previous $4.7B in CIDP, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx downgraded to Neutral from Outperform at Baird
- argenx: Strong Growth and Pipeline Potential Already Priced In, Warranting a Neutral/Hold Rating
- Argenx Moves Ahead With Its Phase 2 Study on ARGX-119 for Pediatric SMA
- Argenx price target raised to $925 from $860 at RBC Capital
- Argenx Se: Strategic Focus and Growth Potential in Graves’ Disease Treatment Justifies Buy Rating